Case Report: Associated Ocular Adverse Reactions With Inactivated COVID-19 Vaccine in China

Kunpeng Pang, Lijie Pan, Hui Guo, Xinyi WuFrontiers in Medicine 2022 · DOI

TL;DR

This case series reports on nine patients in China who experienced ocular adverse reactions within two weeks of receiving an inactivated COVID-19 vaccine. While a causal link cannot be definitively established, the findings highlight the importance of ophthalmologists being aware of and monitoring for these potential side effects following vaccination.

What Problem Does This Paper Address?

The COVID-19 pandemic has led to a rapid global rollout of vaccines, with inactivated vaccines being a significant component, particularly in China. While vaccines are crucial for disease control, understanding their full spectrum of side effects is essential for public health and clinical practice. This paper addresses the need to document and draw attention to potential ocular adverse reactions associated with inactivated COVID-19 vaccines, as these may not be widely recognized or systematically reported. The authors aim to inform the medical community, especially ophthalmologists, about these occurrences to ensure appropriate patient care and monitoring.

Methods

This study is a case series reporting on patients who presented with ocular complaints after receiving an inactivated COVID-19 vaccine. The researchers collected data from nine patients (involving twelve eyes) at the Department of Ophthalmology, Qilu Hospital of Shandong University, between March and August 2021. The primary inclusion criterion was the development of ocular symptoms within 14 days of vaccination. Standard ophthalmological examination techniques were employed, including:

  • Slit-lamp examination: For detailed anterior segment assessment.
  • Optical Coherence Tomography (OCT): Using a spectral-domain machine (Carl Zeiss Cirrus HD-OCT 5000) to visualize retinal layers.
  • Fundus Photography: Using a Carl Zeiss VISUCAM 224 camera for posterior segment imaging.
  • Intraocular Pressure (IOP) Measurement: Using a Topcon, Japan CT 80.
  • Intraocular Fluid Testing: Performed in Beijing GiantMed Diagnostics.

Clinical data, including age, sex, medical history, and the timing and nature of ocular symptoms, were collected. The authors then categorized the diagnosed ocular conditions.

Datasets

Not discussed in the paper. The study relies on clinical data from individual patients presenting to the hospital.

Key Insights and Ideas

  • Ocular Manifestations Post-Vaccination: The study demonstrates that a range of ocular conditions, including choroiditis, uveitis, keratitis, scleritis, acute retinal necrosis, and iridocyclitis, can occur shortly after receiving inactivated COVID-19 vaccines.
  • Timing of Onset: The majority of ocular adverse events appeared within 7.1 days (average) of vaccination, with a range of 1-14 days, suggesting a potential temporal association.
  • Demographic Trends: A notable proportion of the affected patients were women (77.8%), which aligns with some previous observations in vaccine-associated uveitis.
  • Importance of Vigilance: Even though a direct causal link cannot be proven from this case series, the findings underscore the necessity for physicians to maintain a high index of suspicion for ocular side effects following COVID-19 vaccination.
  • Potential for Immune System Modulation: The discussion suggests that adjuvants in vaccines might play a role in triggering immune responses that could lead to ocular inflammation or reactivation of latent viruses.

Key Results

The study reported on 9 patients (12 eyes) who experienced ocular adverse events after inactivated COVID-19 vaccination. The mean age was 44.7 ± 16.5 years, and 77.8% were women. The average time to onset of ocular symptoms was 7.1 days post-vaccination. The specific diagnoses included:

  • Choroiditis: 1 patient
  • Uveitis: 1 patient
  • Keratitis: 4 patients
  • Scleritis: 1 patient
  • Acute Retinal Necrosis: 1 patient
  • Iridocyclitis: 1 patient

Most cases showed improvement with appropriate treatment, including topical or oral steroids, antivirals, and immunosuppressants.

Limitations and Future Work

Limitations:

  • Causal Relationship: The authors explicitly state that a causal relationship between the vaccine and the ocular adverse events cannot be established from this case series. This is a fundamental limitation of observational studies, especially case series.
  • Small Sample Size: Nine patients is a relatively small number, limiting the generalizability of the findings.
  • Lack of Control Group: Without a control group of vaccinated individuals who did not experience ocular issues, it's difficult to determine the true incidence of these reactions.
  • Potential for Coincidence: The temporal association does not prove causation, and some events might have occurred coincidentally.

Future Work:

  • Larger-Scale Studies: The authors suggest the need for larger, prospective studies and robust epidemiological surveillance to better understand the incidence and spectrum of ocular adverse events.
  • Mechanistic Investigations: Further research into the precise immunological mechanisms linking inactivated COVID-19 vaccines to ocular inflammation is warranted.
  • Long-Term Monitoring: Continued monitoring of vaccinated individuals for any delayed ocular complications is important.
  • Distinguishing Vaccine Types: Future studies could explore if different types of COVID-19 vaccines (e.g., mRNA vs. inactivated) have different ocular side effect profiles.

Summary updated

Abstract

The vaccine is still the best clinical measure for effective prevention and control of coronavirus disease 2019 (COVID-19). The vaccine-associated ocular adverse reactions should be noted in detail among the medical community. We reported twelve eyes of 9 patients presented at the Department of Ophthalmology, Qilu Hospital of Shandong University from March to August 2021 with ocular complaints following COVID-19 vaccination. The main inclusion criterion was the development of ocular symptoms within 14 days after receiving a dose of an inactivated COVID-19 vaccine. The mean (SD) age was 44.7 ± 16.5 years (range, 19-78 years), among which seven (77.8%) cases were women. The mean time of ocular adverse events was 7.1 days (range, 1-14 days) after receiving the inactivated COVID-19 vaccine. One patient was diagnosed with choroiditis, 1 with uveitis, 4 with keratitis, 1 with scleritis, 1 with acute retinal necrosis, and 1 with iridocyclitis. Although the causal relationship between vaccines and ocular adverse events cannot be established from this case series report, physicians should pay attention to the ocular adverse reactions following the COVID-19 vaccine administration.
BibTeX
@inproceedings{pang2022case,
  author = {Kunpeng Pang and Lijie Pan and Hui Guo and Xinyi Wu},
  title = {{Case Report: Associated Ocular Adverse Reactions With Inactivated COVID-19 Vaccine in China}},
  booktitle = {Frontiers in Medicine},
  year = {2022},
  doi = {10.3389/fmed.2021.823346},
}
Figure